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Abstract
The metabolic and immune adaptation to extracellular signals allows macrophages 
to	carry	out	specialized	functions	involved	in	immune	protection	and	tissue	homeo-
stasis.	Nuclear	 factor	 erythroid	 2-related	 factor	 2	 (NRF2)	 is	 a	 transcription	 factor	
that	coordinates	cell	redox	and	metabolic	responses	to	stressors.	However,	the	in-
dividual	and	concomitant	activation	of	NRF2	and	inflammatory	pathways	have	been	
poorly investigated in isolated macrophages. We here took advantage of reporter 
mice	for	the	transcriptional	activities	of	NRF2	and	nuclear	factor-kB	(NFκB),	a	key	
transcription	 factor	 in	 inflammation,	 and	 observe	 a	 persisting	 reciprocal	 interfer-
ence	 in	the	response	of	peritoneal	macrophages	to	the	respective	activators,	 tert-
Butylhydroquinone	(tBHQ)	and	lipopolysaccharide	(LPS).	When	analyzed	separately	
by	gene	expression	studies,	these	pathways	trigger	macrophage-specific	metabolic	
and proliferative target genes that are associated with tBHQ-induced pentose phos-
phate	pathway	(PPP)	with	no	proliferative	response,	and	with	opposite	effects	ob-
served	with	LPS.	Importantly,	the	simultaneous	administration	of	tBHQ	+	LPS	alters	
the	effects	of	each	individual	pathway	in	a	target	gene-specific	manner.	In	fact,	this	
co-treatment	potentiates	the	effects	of	tBHQ	on	the	antioxidant	enzyme,	HMOX1,	
and	the	antibacterial	enzyme,	IRG1,	respectively;	moreover,	the	combined	treatment	
reduces	tBHQ	activity	on	the	glycolytic	enzymes,	TALDO1	and	TKT,	and	decreases	
LPS	effects	on	the	metabolic	enzyme	IDH1,	the	proliferation-related	proteins	KI67	
and	PPAT,	and	the	inflammatory	cytokines	IL-1β,	IL-6,	and	TNFα.	Altogether,	our	re-
sults	show	that	the	activation	of	NRF2	redirects	the	metabolic,	immune,	and	prolif-
erative	response	of	peritoneal	macrophages	to	 inflammatory	signals,	with	relevant	
consequences for the pharmacological treatment of diseases that are associated with 
unopposed inflammatory responses.
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1  | INTRODUC TION
Tissue-resident	 macrophages,	 such	 as	 those	 populating	 the	 peri-
toneal	cavity	or	brain,	derive	from	progenitor	cells	 that	self-renew	
and differentiate locally under the influence of microenvironmental 
cues.1,2	These	immune	cells	are	extremely	reactive	and,	in	response	
to	a	broad	variety	of	physiological	and	pathological	stimuli,	activate	
a spectrum of different transcriptional programs and functional 
responses,	 simplistically	 included	within	 two	 extreme	 phenotypes	
defined	 as	 “classical”,	 or	M1,	 and	 “alternative”,	 or	M2,	 activation.3 
Binding of macrophages to pathogens induces a series of antibacte-
rial	responses	through	the	activation	of	transcription	factors,	among	
which	nuclear	factor-kB	(NFκB)	plays	a	central	role,	and	the	robust	
production	of	inflammatory	cytokines,	such	as	IL-1β,	IL-6,	and	TNFα. 
On	the	other	hand,	Th2	cytokines	induce	the	expression	of	proteins,	
such	as	arginase	1	(ARG1),	that	trigger	the	anti-inflammatory	and	tis-
sue	repairing	activities	of	M2	macrophages.4
In order to meet the energy demand required for functional spe-
cialization,	M1	macrophages	are	characterized	by	a	metabolic	shift	to-
ward	aerobic	glycolysis,	 carbon	 flux	 through	 the	pentose	phosphate	
pathway	 (PPP),	 and	 fatty	 acid	 synthesis,	 with	 truncated	 TCA	 cycle,	
which allows to rapidly produce energy for bactericidal functions and 
self-renewal.	Hence,	along	with	 inflammatory	mediators,	also	robust	
changes	in	the	expression	of	metabolic	enzymes	accompany	the	M1	
polarization	of	macrophages	and	even	sustain	their	immune	function.	
In	fact,	the	mitochondrial	metabolite	itaconate	is	endowed	with	bacte-
ricidal	activity	and	derives	from	the	activity	of	the	enzyme	IRG1	whose	
expression is highly induced in inflammatory macrophages.5-8	 Thus,	
elucidating the interconnections between immune and metabolic re-
sponses in macrophages might help in understanding the physiology 
of cell adaptation and the pathological consequences of unopposed or 
elusive inflammatory responses.9
Nuclear	 factor	 erythroid	 2-related	 factor	 2	 (NRF2)	 is	 a	 tran-
scription factor deeply implicated in cell adaptation to stressors. 
Under	unstimulated	conditions,	binding	to	the	cytoplasmic	protein	
KEAP1	leads	to	NRF2	degradation.	Exposure	to	oxidative	or	electro-
philic	compounds,	such	as	tert-Butylhydroquinone	(tBHQ),	disrupts	
KEAP1-NRF2	 binding	 and	 allows	NRF2	 to	migrate	 to	 the	 nucleus	
and	 bind	 antioxidant	 responsive	 elements	 (AREs)	 within	 target	
genes,	 following	 heterodimerization	with	MAF	 proteins.10 The re-
sulting transcriptional program allows detoxification from the initial 
chemical stressor and the activation of cytoprotective antioxidative 
reactions.	 More	 recent	 studies,	 using	 animal	 models	 of	 dysregu-
lated inflammation which also carry genetic manipulations of the 
KEAP1-NRF2	complex,	demonstrated	 that	NRF2	 is	also	necessary	
for	mounting	an	appropriate	innate	immune	response,	as	its	activity	
has been associated with a reduced production of pro-inflammatory 
cytokines during inflammation.11-15	 In	 general,	 the	metabolic	 shift	
that accompanies cell adaption to stressors has been associated with 
NRF2-mediated	generation	of	anabolic	precursors	and	NADPH.16,17 
However,	the	specific	metabolic	response	of	macrophages	and	their	
adaptation	 to	 the	 simultaneous	 activation	of	NRF2	and	 inflamma-
tory	 pathways	 needs	 further	 investigation,	 as	 mostly	 approached	
with	experimental	systems,	such	as	in	vitro	differentiated	cells	or	cell	
lines,	that	profoundly	differ	from	resident	macrophages,	particularly	
in	cell	phenotype	and	immunometabolism.	Instead,	it	is	important	to	
deciphering the complexity of macrophage immune-metabolic net-
work under multiple activatory stimuli and through the use of a more 
reliable experimental model of tissue-resident macrophages.
The aim of the present study is thus to use primary cultures of 
peritoneal macrophages and evaluate their immune and metabolic 
responses	to	the	NRF2-activator,	tBHQ,	and	the	bacterial	wall	com-
ponent,	lipopolysaccharide	(LPS).	Exploiting	the	availability	of	NRF2	
and	NFκB	 reporter	mice,	we	 here	 show	 that	 the	 concomitant	 ad-
ministration	of	tBHQ	and	LPS	to	macrophages	modifies	the	antiox-
idant,	metabolic,	inflammatory,	and	proliferative	responses	induced	
by	each	individual	signal	and	suggest	that	NRF2	is	able	to	redirect	
macrophage immunometabolism during infections or inflammatory 
conditions.
2  | METHODS
2.1 | Animals and treatment
C57BL/6	female	mice	of	4	months	of	age	were	supplied	by	Charles	
River	Laboratories	(Calco,	Italy)	and	used	for	gene	expression	analy-
ses.	Animals	were	allowed	to	food	and	water	access	ad	libitum	and	
kept in temperature-controlled facilities on a 12-hour light and 
dark	 cycle.	Animals	were	housed	 in	 the	animal	 care	 facility	of	 the	
Department of Pharmacological and Biomolecular Sciences at the 
University	of	Milan.	Animal	investigation	has	been	conducted	in	ac-
cordance with the ethical standards and according to the Declaration 
of	Helsinki	 and	 to	 the	Guide	 for	 the	Care	 and	Use	 of	 Laboratory	
Animals,	as	adopted	and	promulgated	by	the	US	National	Institute	of	
Health,	and	in	accordance	with	the	European	Guidelines	for	Animal	
Care	and	Use	of	Experimental	Animals.	Animals	were	sacrificed	by	a	
lethal	ketamine/xylazine	solution	(150	and	12	mg/kg,	respectively).	
Generation	of	NFκB-Luc	and	ARE-luc2	animals	has	already	been	de-
scribed18,19;	 female	mice	were	used	at	4	months	of	age.	All	animal	
experiments	were	approved	by	the	Italian	Ministry	of	Research	and	
University	and	controlled	by	an	academic	panel	of	experts.
2.2 | Primary cultures of peritoneal macrophages
Peritoneal cells were recovered by peritoneal lavage as previously 
described.20	Briefly,	5	mL	of	prechilled	0.9%	NaCl	was	injected	into	
the	peritoneal	cavity	using	a	21	G	needle,	and	cell	suspension	was	
recovered	 and	 centrifuged;	 following	 incubation	with	ACK	 solu-
tion	(0.15-mol/L	NH4Cl,	1-mmol/L	KHCO3,	and	0.1-mmol/L	EDTA;	
pH	 7.3)	 for	 5	minutes	 at	 4°C,	 cells	 were	 seeded	 at	 the	 concen-
tration of 1 × 106	 cells/mL	 in	RPMI	 (Life	Technology-Invitrogen)	
supplemented	 with	 10%	 endotoxin-free	 FBS,	 1%	 penicillin/
streptomycin,	and	1%	Na-pyruvate.	After	45	minutes	and	several	
washes	 in	PBS,	the	medium	was	replaced	with	RPMI	w/o	phenol	
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red	 supplemented	with	10%	dextran-coated	charcoal	 (DCC)-FBS	
(RPMI	+	10%	DCC).	On	the	next	day,	cells	were	treated	with	ve-
hicle	(DMSO	20%	in	H2O),	tBHQ	(100	µmol/L),	LPS	(1	µg/mL),	or	
the	combination	of	the	two	stimuli	 for	3,	6,	or	16	h,	as	specified	
in each experiment. Cell suspension was centrifuged at 1200× g,	
cell	pellets	were	re-suspended	in	TRIzol	reagent	(Life	Technology-
Invitrogen),	and	stored	at	−80°C	for	RNA,	while	supernatant	was	
stored	 for	 ELISA	 analyses.	 tBHQ	 induces	 a	 strong	 antioxidant	
response	 through	mitochondrial	 oxidative	 stress	 and	NRF2	 acti-
vation,21 without inducing cell toxicity in our experimental condi-
tions	(data	not	shown).
2.3 | RNA preparation and expression analyses
Total	 RNA	 was	 purified	 using	 Direct-zol	 RNA	 Miniprep	 (Zymo	
Research),	according	to	the	manufacturer's	instructions,	including	
a	step	with	deoxyribonuclease	incubation.	For	real-time	PCR,	200-
ng	RNA	was	used	for	cDNA	preparation	using	8	U/μL	of	Moloney	
murine	 leukemia	 virus	 reverse	 transcriptase	 (Promega)	 in	 a	 final	
volume of 25 μL.	The	reaction	was	performed	at	37°C	for	1	hour,	
and	the	enzyme	was	inactivated	at	75°C	for	5	minutes.	Control	re-
actions	without	the	addition	of	the	reverse	transcription	enzyme	
were	performed	 (data	not	 shown).	A	1:4	cDNA	dilution	was	am-
plified	using	GoTaq®	qPCR	Master	Mix	technology	(Promega)	ac-
cording	to	the	manufacturer's	protocol.	The	PCR	was	carried	out	
in	triplicate	on	a	96-well	plate	using	QuantStudio® 3 real-time PCR 
system	 (Applied	 Biosystems)	 with	 the	 following	 thermal	 profile:	
2	minutes	at	95°C;	40	cycles,	15	seconds	at	95°C,	and	1	minutes	
at	 60°C.	 Primer	 sequences	 are	 reported	 in	 Table	 S1.	Data	were	
analyzed	using	 the	2−ΔΔCt	method	and	normalized	using	36b4	as	
housekeeping gene.
2.4 | Luciferase enzymatic assay
Cells	 were	 lysed	 with	 Luciferase	 Cell	 Culture	 Lysis	 Reagent	
(Promega)	 and	 the	 luciferase	 assay	 was	 carried	 out	 in	 luciferase	
assay	buffer	(470-μm	luciferin,	20-mm	Tricine,	0.1-mm	EDTA,	1.07-
mm	(MgCO3)4·Mg(OH)2	×	5H2O;	2.67-mm	MgSO4	×	7H2O	in	H2O,	
pH	7.8,	with	 33.3-mm	DTT	 and	 530-μm	ATP),	 using	 20	μL	 of	 cell	
lysate and 100 μL	 of	 luciferase	 assay	 buffer.	 Luminescence	 emis-
sion	was	measured	with	a	Veritas	 luminometer	 (Promega).	Protein	
concentration was determined by the Bradford assay and used to 
normalize	luciferase	units/μg	protein,	obtaining	the	relative	lumines-
cence	units	(RLU).
2.5 | ELISA assay
Culture medium from peritoneal macrophages treated with differ-
ent	combinations	of	tBHQ	and	LPS	was	assayed	for	IL-1β,	IL-6,	and	
TNFα	 protein	 levels	by	enzyme	 immunoassay	 (murine	ELISA	kits	
from	Bio-Techne).	Dilutions	of	1:10	were	made	for	IL-6	and	TNFα 
assays.
2.6 | Statistical analyses
All	data	are	presented	as	mean	±	SEM	of	three	observations.	Unless	
otherwise	indicated,	results	were	analyzed	by	one-way	ANOVA	fol-
lowed	by	Bonferroni	multiple	comparison	test.	A	statistical	level	of	
significance of P < .05 was accepted. Statistical analysis was per-
formed	using	GraphPad	Prism	software,	version	8.
3  | RESULTS
3.1 | Reciprocal interference between NRF2 and 
NFκB transcriptional activities in macrophages
Although	 cell	 metabolism	 and	 immune	 functions	 are	 strictly	 inter-
connected	in	macrophage	physiology,	the	effects	of	the	concomitant	
activation	 of	 inflammatory	 and	 NRF2-activating	 signals	 in	 the	 im-
munometabolic adaptation of resident macrophages are still poorly 
defined.	We	 first	 took	 advantage	of	 the	ARE-luc2	 reporter	mice,	 a	
transgenic	strain	engineered	to	express	enzyme	luciferase	under	the	
control	 of	 AREs-containing	 promoter,18 to readily obtain biological 
evidence	of	the	 influence	of	 inflammatory	signals	on	NRF2	activity.	
Primary	cultures	of	peritoneal	macrophages	were	obtained	from	ARE-
luc2	mice,	treated	with	tBHQ	and	LPS,	either	alone	or	in	combination,	
and protein extracts were prepared after 6 and 16 hours to measure 
bioluminescence	emission.	As	expected,	treatment	with	tBHQ	results	
in the increase of luciferase activity that is proportion with the time of 
incubation,	reflecting	the	induction	of	NRF2-driven	transcription	(see	
Figure	1A).	Also,	LPS	induces	similar	although	much	weaker	effects	as	
compared	with	tBHQ,	supporting	the	notion	that	inflammatory	signals	
induce	NRF2	transcriptional	activity	in	macrophages.	Importantly,	the	
tBHQ +	LPS	treatment	potentiates	both	the	short-	and	long-term	ef-
fects	of	tBHQ	alone	on	NRF2	transcriptional	activity,	suggesting	that	
inflammatory conditions are able to influence the pharmacologically 
induced	activity	of	NRF2	in	macrophages.
We	then	asked	whether	 the	pharmacological	activation	of	NRF2	
causes	the	metabolic	and	immune	reprograming	of	M1	macrophages.	
To	this	aim,	we	used	the	NFκB-luc2	reporter	mice,	engineered	to	ex-
press	the	luciferase	enzyme	under	the	control	of	a	promoter	contain-
ing	NFκB-responsive elements.19	NFκB-luc2 peritoneal macrophages 
were	treated	as	reported	above.	As	expected,	LPS	induces	luciferase	
activity	 in	a	 time-dependent	manner,	with	10-	and	3-fold	 inductions	
observed	after	6	and	16	hours,	respectively	(see	Figure	1B).	Both	short	
and	prolonged	NFκB-mediated transcriptional effects are reduced with 
the tBHQ +	LPS	treatment;	interestingly,	tBHQ	alone	also	provides	in-
hibitory	 effects	 at	 the	 later	 time	point	 analyzed.	 Thus,	 these	 results	
suggest	that	the	pharmacological	activation	of	NRF2	modifies	the	in-
flammatory	response	of	macrophages	to	LPS	by	triggering	significant	
and	persisting	inhibitory	effects	on	NFκB transcriptional activity.
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3.2 | Validation of NRF2 target genes in 
macrophages
By coupling an antioxidant activity with a shift in energetic metabo-
lism,	 the	 NRF2-mediated	 response	 is	 a	 key	 system	 in	 cell	 protec-
tion	against	oxidative	stress.	Diverse	NRF2	target	genes	have	been	
identified,	 depending	 on	 the	 cell	 type	 analyzed	 and	 specific	 func-
tion	required	by	NRF2	activation.	In	order	to	study	the	endogenous	
transcriptional	activity	of	NRF2	in	peritoneal	macrophages,	we	first	
performed dose- and time-dependent experiments with tBHQ and 
assessed	the	mRNA	abundance	of	candidate	target	genes.	As	shown	
in	Figure	2A,	the	mRNA	levels	coding	the	antioxidant	protein	HMOX1	
are readily increased by high concentrations of tBHQ with stronger ef-
fects detected at later time points; also Nqo1	mRNA	levels	are	induced	
in	a	time-	and	dose-dependent	manner,	although	with	a	lower	efficacy	
(see	Figure	S1).	In	parallel,	we	analyzed	the	expression	of	NRF2	tar-
get	metabolic	enzymes,	namely	transaldolase-1	(TALDO1)	and	tran-
sketolase	 (TKT),	 that	 sustain	 the	 PPP	 associated	 with	 macrophage	
polarization,	 as	 well	 as	 phosphoribosyl	 pyrophosphate	 amidotrans-
ferase	 (PPAT),	 a	 rate-limiting	 enzyme	 in	 purine	 biosynthesis	 which	
has	been	reported	to	be	 increased	by	NRF2	activity	 in	proliferating	
cancer cells.11,22	Figure	2B	shows	that	Taldo1	mRNA	levels	increase	in	
a	dose-	and	time-dependent	manner	following	NRF2	chemical	activa-
tion,	while	 later	time	points	and	higher	concentrations	of	tBHQ	are	
necessary to increase Tkt	expression.	Unexpectedly,	the	mRNA	levels	
encoding	PPAT	are	not	modified	by	tBHQ	at	any	concentration	used.
Altogether,	 these	 experiments	 provide	 the	 dynamics	 of	 redox	
and metabolic gene expression that is induced by the pharmacologi-
cal	activation	of	NRF2	in	peritoneal	macrophages.
3.3 | Modulation of metabolic, cell cycle, and 
inflammation-related genes by tBHQ and LPS in 
macrophages
Metabolic	 adaptation	 and	 immune	 activation	 are	 interlinked	 and	
concomitant events in macrophage immune response. The results of 
Figure	1	 lead	us	 to	predict	 that	 inflammatory	 conditions	 and	NRF2	
activation reprogram the transcriptional effects induced by each 
signaling	pathway,	causing	a	reciprocal	interference	with	macrophage	
immunometabolism. Separated or combined treatments with tBHQ 
and	LPS	were	used	 in	time-course	experiments	to	assess	NRF2	and	
LPS	target	gene	expression.	In	line	with	the	positive	effects	of	LPS	on	
NRF2	activity	shown	in	Figure	1A,	we	observed	that	the	increase	in	
Hmox1	mRNA	induced	by	short-term	tBHQ	treatment	potentiates	the	
inflammatory	signal	 (see	Figure	3A).	On	the	contrary,	 the	combined	
tBHQ +	LPS	treatment	causes	a	reduction	in	the	effects	of	tBHQ	alone	
on	the	expression	of	the	NRF2	target	metabolic	enzymes	TALDO1	and	
TKT	(see	Figure	3B).	Unexpectedly,	we	also	observed	that	treatment	
with	LPS	alone	significantly	reduces	Taldo1 and Tkt	mRNA	levels,	while	
it	 increases	the	expression	of	PPAT,	an	enzyme	 involved	 in	de	novo	
purine	biosynthesis,	 suggesting	that	LPS	may	reduce	energy	 fueling	
through	the	PPP,	as	already	reported,23	and	support	cell	proliferation,	
which	 still	 needs	 biological	 confirmation.	 Thus,	 these	 results	 show	
that	LPS	regulates	gene	expression	in	a	peritoneal	macrophage-spe-
cific manner and that it is able to modify the transcriptional effects of 
NRF2	associated	with	cell	redox	and	metabolic	adaptation.
To	analyze	the	NRF2-mediated	interference	with	the	metabolic	
effects	 of	 LPS,	we	 took	 advantage	 of	 the	 fact	 that	 the	metabolic	
F I G U R E  1   Regulation of luciferase reporter activity by oxidative 
and	inflammatory	stimuli	in	peritoneal	macrophages	from	ARE-
luc2	and	NFκB-luc2 mice. Peritoneal macrophages isolated from 
ARE-luc2	(A)	and	NFκB-luc2	(B)	reporter	animals	were	used	to	assay	
NRF2	and	NFκB transcriptional activity. Cells were treated with 
vehicle	(veh,	open	boxes),	tBHQ	(grey	boxes),	LPS	(filled	boxes),	
or	the	combination	of	the	two	stimuli	(dashed	grey	boxes)	and	
luminescence	measured	after	6	or	16	h,	as	indicated.	Luciferase	
activity	is	represented	as	relative	luciferase	units	(RLU)	per	μg 
protein	and	expressed	in	relation	with	6-h	veh-treated	samples,	
which was given the arbitrary value of 1. Data are presented as 
mean values ±	SEM	(n	=	3)	of	a	single	experiment	representative	of	
at	least	two	other	independent	experiments.	Results	were	analyzed	
by	one-way	ANOVA	followed	by	Bonferroni's	multiple	comparisons	
test. (df =	11;	A)	6	h:	F =	351.2,	16	h:	F =	405.3;	B)	6	h:	F =	355.6,	
16 h: F =	233.9).	(*)	P <	.05,	(**)	P <	.01,	(***)	P < .001 vs 6 h veh; (##)	
P < .001 vs tBHQ; ($$)	P <	.001	vs	LPS
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signature	of	M1	macrophages	 is	characterized,	among	others,	by	a	
truncated	TCA	cycle.24 We thus assayed the expression of isocitrate 
dehydrogenase	 (IDH1)	and	 immune-responsive	gene	1	 (IRG1),	 two	
key	enzymes	in	macrophage	TCA	cycle	that	display	opposite	activ-
ities on citrate metabolism.7,25	 According	 to	 published	 data,9	 LPS	
downregulates	 the	mRNA	 levels	 of	 Idh1 and strongly upregulates 
those coding Irg1	in	peritoneal	macrophages,	as	shown	in	Figure	3C.	
More	importantly,	these	effects	are	significantly	different	following	
the	combined	treatment	with	LPS	+	tBHQ.	In	fact,	this	association	
reduces	 the	 inhibitory	 effects	 of	 LPS	 on	 Idh1 and potentiates its 
long-term effects on Irg1	mRNA	levels.
Since	metabolic	adaptation	to	LPS	is	supposed	to	correlate	with	
cell	proliferation,	we	assessed	 the	expression	of	KI67,	a	marker	of	
proliferating	cells.	The	results	are	reported	in	Figure	3D	and	show	
that	LPS	 induces	an	 immediate	and	persistent	 increase	 in	Ki67 ex-
pression and that the co-administration of tBHQ significantly re-
duces	this	effect,	in	agreement	with	what	is	shown	in	Figure	4C	on	
the	expression	of	PPAT,	the	enzyme	involved	in	de	novo	purine	bio-
synthesis. These results suggest that inflammatory stimuli sustain 
the	proliferation	of	peritoneal	macrophages,	a	response	that	is	sig-
nificantly	reduced	by	the	simultaneous	activation	of	NRF2.
Since metabolic adaptation is strongly connected to immune 
activation,	we	extended	our	analyses	to	inflammatory	gene	expres-
sion.	As	expected,	treatment	of	peritoneal	macrophages	with	LPS	in-
creases	the	mRNA	levels	coding	IL-1β,	IL-6,	and	TNFα.	Interestingly,	
we observed a significant reduction of Il-1β and Il-6	mRNA	levels	fol-
lowing tBHQ +	LPS	as	compared	to	LPS	alone,	with	a	more	persistent	
inhibition of IL-1β.	We	also	analyzed	TNFα,	since	its	expression	is	dif-
ferentially regulated by inflammatory stimuli.26	Indeed,	we	observed	
that the combined tBHQ +	LPS	treatment	only	slightly	reduces	the	
early	effect	of	LPS,	without	reaching	statistical	significance,	on	TNFα 
mRNA	levels;	conversely,	it	increases	the	response	to	the	endotoxin	
at	the	later	time	point	(see	Figure	4A).	Notably,	when	added	alone,	
tBHQ also induces a delayed reduction of Il-1β and Il-6	mRNA	levels,	
as compared to controls. In order to obtain a biological evidence for 
the	immune	regulatory	effects	of	NRF2	on	macrophage	immune	ac-
tivation,	we	assessed	the	cytokine	protein	levels	that	were	present	
in the culture medium of macrophages treated as above. The results 
reported	in	Figure	4B	confirm	the	data	on	gene	expression	and	show	
that the combined treatment with tBHQ +	LPS	significantly	reduces	
the	 levels	 of	 IL-1β	 and	 IL-6.	 Interestingly,	 also	 TNFα levels are re-
duced	at	the	early	time	point	of	tBHQ	and	endotoxin	treatment,	in-
dicating	an	early	transcriptional	interference	on	this	gene,	which	is	
counteracted	at	later	time	points	only	at	the	mRNA	level.	In	addition,	
we	observed	a	consistent	reduction,	beneath	measurable	levels,	of	
IL-1β,	IL-6,	and	TNFα	when	tBHQ	was	added	alone	to	the	cells.	Thus,	
NRF2	activation	during	the	inflammatory	response	induces	anti-in-
flammatory effects through gene-specific dynamic effects.
Altogether,	these	results	show	that	the	NRF2	and	LPS	pathways,	
when	analyzed	separately,	 induce	a	macrophage-specific	subset	of	
F I G U R E  2  Time-	and	dose-dependent	effect	of	NRF2	activation	on	NRF2	target	genes	in	peritoneal	macrophages.	The	expression	of	
candidate	NRF2	target	genes	was	measured	in	peritoneal	macrophages	treated	with	vehicle	(open	triangles)	or	increasing	concentrations	of	
tBHQ (1 µmol/L,	filled	circles;	10	µmol/L,	filled	triangles;	100	µmol/L,	filled	squares)	for	3,	6,	and	16	h,	as	indicated.	Real-time	PCR	was	used	
to	analyze	the	mRNA	levels	coding	for	(A)	HMOX1	and	(B)	TALDO1,	TKT,	and	PPAT.	Data	sets	for	each	gene	were	calculated	using	the	2−ΔΔCt 
method and expressed in relation to 3 h veh samples. Data are presented as mean values ±	SEM	(n	=	3)	of	a	single	experiment	representative	
of	at	least	two	other	independent	experiments.	Results	were	analyzed	by	two-way	ANOVA	followed	by	Dunnett's	multiple	comparisons	test	
(HMOX1,	F(3,24)	=	400.8;	TALDO1,	F(3,24)	=	122.9;	TKT,	F(3,24)	=	18.56;	PPAT,	F(3,24)	=	14.74).	(*)	P <	.05;	(**)	P <	.01,	(***)	P < .001 vs 
veh
(A)
(B)
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target	genes,	and	that	the	inflammatory	response	of	resident	macro-
phages	can	be	regulated	by	the	pharmacological	activation	of	NRF2	
by	reprograming	the	expression	of	metabolic,	proliferative,	and	in-
flammatory genes.
4  | DISCUSSION
NRF2	is	a	key	transcriptional	regulator	of	detoxification	and	redox	
balance	 that	 protects	 cells	 against	 chemical	 stressors.	 Recently,	
NRF2	became	an	attractive	target	for	immune-regulatory	therapies,	
as	a	negative	 role	 for	NRF2	activation	on	 inflammatory	 responses	
was	 demonstrated	 using	 in	 vivo	 LPS-mediated	 animal	 models	 or	
in	 vitro	 differentiated	 macrophages,	 also	 bearing	 Keap1 and Nrf2 
gene deletions.14,27 Our results extend this knowledge to peritoneal 
macrophages	and	show	that	the	pharmacological	activation	of	NRF2	
interferes	with	the	macrophage	response	to	LPS,	not	only	by	reduc-
ing inflammatory gene expression but also by altering the expression 
of	metabolic	enzymes	involved	in	cell	phenotypic	activation.
Initially,	 the	 anti-inflammatory	 activity	 of	 NRF2	 has	 been	 as-
cribed	to	the	upregulation	of	antioxidant	enzymes	that	are	able	to	
eliminate	ROS;	more	recently,	NRF2	has	been	shown	to	inhibit	the	
activity	 of	 the	 inflammatory	 transcription	 factor,	NFκB.12 The use 
of reporter mice in the present study allowed us to confirm this 
hypothesis,	 as	 we	 observed	 a	 persistent	 reduction	 of	 NFκB tran-
scriptional	 activity	 in	 response	 to	NRF2	 activation.	Moreover,	we	
here show that the inhibitory effects of the combined tBHQ +	LPS	
treatment,	 as	 compared	with	 those	 induced	by	 the	 two	 individual	
signals,	occur	on	both	antioxidant	and	 inflammatory	genes	shortly	
after	 their	 administration	 to	macrophages	 (see	 Figures	 3A	 and	 4),	
F I G U R E  3   Target gene expression 
following the concomitant activation 
of	NRF2	and	LPS-activating	signals	in	
peritoneal macrophages. The expression 
of	NRF2	and	LPS	target	genes	was	
evaluated in peritoneal macrophages 
treated	with	vehicle	(veh,	white	bars),	
tBHQ	(grey	bars),	LPS	(black	bars),	and	the	
combination of the two stimuli (dashed 
grey	bars)	for	3	or	16	h,	as	indicated.	Real-
time	PCR	was	used	to	analyze	the	mRNA	
levels	coding	(A)	HMOX1	(B,	C)	TALDO1,	
TKT	IDH1,	IRG1,	and	PPAT,	and	(D)	KI67.	
Data sets for each gene were calculated 
using the 2−ΔΔCt method and expressed 
in relation to 3 h veh samples. Data are 
presented as mean values ±	SEM	(n	=	3)	
of a single experiment representative of at 
least two other independent experiments. 
Results	were	analyzed	by	one-way	
ANOVA	followed	by	Bonferroni's	multiple	
comparisons test. (df =	11;	HMOX1,	
3 h: F =	0.7,	16	h	=	1.074;	TALDO1,	3	h:	
F =	8.255,	16	h:	F =	869.2;	TKT,	3	h:	
F =	1.114,	16	h:	F =	188.7;	IDH1,	3	h:	
F =	93.44,	16	h:	F =	353.1;	IRG1,	3	h:	
F =	21.25,	16	h:	F =	803.1;	PPAT,	3	h:	
F =	12.73,	16	h:	F =	5.013;	KI67	3	h:	
F =	374.2,	16	h:	F =	100.6).	(*)	P <	.05,	
(**)	P <	.01,	(***)	P < .001 vs 6 h veh; (###)	
P < .001 vs tBHQ; ($$$)	P <	.001	vs	LPS
(A)
(B)
(C)
(D)
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suggesting that the downstream biochemical processes activated 
by	this	 treatment	proceed	 in	parallel	and,	probably,	 independently	
from each other. The molecular mechanisms underlying the interfer-
ence	between	NRF2	and	LPS-induced	inflammatory	mediators,	such	
as	 NFκB,	 are	 still	 not	 fully	 elucidated.	 Previous	 evidence	 showed	
that	NRF2	 is	 able	 to	 physically	 interact	with	 Pol	 II	 and	 reduce	 its	
binding	to	inflammatory	gene	promoters,	or	with	anti-inflammatory	
transcription	factors,	such	as	the	estrogen	and	peroxisome	prolifer-
ator-activated	gamma	receptors,	and	regulate	their	activity	on	gene	
expression.12,28,29	Further	studies	are	needed	to	understand	the	mo-
lecular	mechanism	of	NRF2	activity	in	macrophages.
It has been shown that selected metabolic molecules produced 
by	NRF2	activation	in	response	to	inflammatory	signals	are	able	to	
switch macrophages toward an anti-inflammatory phenotype.27 We 
here further extend this hypothesis and demonstrate that also the 
expression	of	metabolic	genes	 regulated	by	NRF2	or	LPS	 is	 recip-
rocally	 influenced	by	 the	 co-occurrence	of	NRF2	and	 inflammato-
ry-activating signals. This leads us to propose that the shift in energy 
metabolism	and	consumption	allows	NRF2	to	induce	an	integrated	
cellular	response	that	redirects	macrophage	polarization	toward	an	
anti-inflammatory	phenotype.	Interestingly,	we	observed	a	potentia-
tion	of	NRF2	transcriptional	activity	by	LPS,	as	it	results	from	the	use	
of	NRF2	reporter	macrophages	treated	with	LPS	+	tBHQ	(Figure	1)	
that is reflected by the increase in antioxidant gene expression. On 
the	other	hand,	 the	NRF2	positive	effects	on	metabolic	genes	are	
instead	 reduced	by	 LPS,	 further	 supporting	 a	 competition	mecha-
nism	for	gene-specific	transcription	factors,	which	also	need	further	
elucidations.
F I G U R E  4  NRF2-mediated	interference	with	inflammatory	gene	expression	induced	by	LPS	in	peritoneal	macrophages.	The	expression	
of	inflammatory	genes	was	evaluated	in	peritoneal	macrophages	treated	with	vehicle	(veh,	white	bars),	tBHQ	(grey	bars),	LPS	(black	bars),	
and	the	combination	of	the	two	stimuli	(dashed	grey	bars)	for	3	or	16	h,	as	indicated.	A,	Real-time	PCR	was	used	to	analyze	the	mRNA	levels	
coding	IL-1β,	IL-6,	and	TNFα. Data sets for each gene were calculated using the 2−ΔΔCt method and expressed in relation to 3 h veh samples. 
(B)	IL-1β,	IL-6,	and	TNFα	proteins	were	analyzed	by	ELISA	immunoassay	in	the	culture	medium	of	peritoneal	macrophages	treated	as	in	(A).	
Data are presented as mean values ±	SEM	(n	=	3)	of	a	single	experiment	representative	of	at	least	two	other	independent	experiments.	
Results	were	analyzed	by	one-way	ANOVA	followed	by	Bonferroni's	multiple	comparisons	test	(in	A)	df =	11;	IL-1β,	3	h:	F =	482,	16	h:	
F =	203.7;	IL-6	3	h:	F =	332.3,	16	h:	F =	48.32;	TNFα 3 h: F =	58.70,	16	h:	F =	3367;	in	(B),	IL-1β,	df =	8,	F =	244.9;	IL-6,	3	h:	df =	8,	F =	501.4,	
16 h: df =	11,	F =	435.7;	TNFα df =	11,	3	h:	F =	231.8,	16	h:	F =	311.1).	(*)	P <	.05;	(**)	P <	.01;	(***)	P < .001 vs veh; ($$)	P < .01; ($$$)	P < .001 
vs	LPS
(B)
(A)
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Our	 results	demonstrate	a	novel	activity	of	NRF2	 in	 inflamma-
tory macrophages that provides an antiproliferative response. The 
underlying	mechanism	 is	 still	not	clear;	however,	 the	metabolic	ef-
fects	 observed	 following	NRF2	 chemical	 activation	 are	 consistent	
with	 the	 absence	 of	 DNA	 replication.	 In	 fact,	 we	 detected	 an	 in-
creased	expression	of	glycolytic	enzymes	involved	in	the	PPP,	TKT,	
and	TALDO1,	not	paralleled	by	any	effect	on	PPAT,	the	rate-limiting	
enzyme	in	the	de	novo	biosynthesis	of	purines	and	aromatic	amino	
acids	 (see	Figure	2).	Although	the	function	of	TKT	and	TALDO1	in	
the	process	of	macrophage	activation	is	still	not	clear,	these	enzymes	
operate without the need of energy to provide triose-phosphates 
that enter back glycolysis and sustain the cell metabolic switch that 
is necessary for phenotypic activation.17	Thus,	our	data	suggest	that	
NRF2	activation	in	resident	macrophages	promotes	glucose	metab-
olism through the PPP that is not followed by purine synthesis and 
cell proliferation. These data are apparently in contrast with previous 
studies	which	 showed	 a	 positive	 involvement	 of	NRF2	 in	 anabolic	
processes	leading	to	nucleotides	and	amino	acid	synthesis.	Although	
the	reasons	for	this	discrepancy	are	presently	unknown,	we	believe	
that the use of primary cultures of nonelicited peritoneal macro-
phages in the present study allows to appreciating the reactivity 
and	specialized	functions	of	this	subpopulation	of	resident	immune	
cells,	 including	 self-renewal,	 highlighting	 distinctions	 from	 macro-
phage-like cells derived from in vitro differentiation of monocytes 
or	bone	marrow	precursor	cells,	or	transformation	into	immortalized	
cell lines.
The choice of the experimental system appears also an asset 
for the study of macrophage immunometabolism that mimics the 
pathophysiologic	condition.	In	fact,	it	appears	crucial	to	understand	
the ability of macrophages to respond simultaneously to diverse 
stimuli	and	coordinate	 their	activation	with	 time,	similarly	 to	what	
is occurring in tissues when multiple and simultaneous activation 
events skew macrophage immunometabolism by altering the mo-
lecular	mechanisms	that	initiate	and	amplify	cell	polarization.22 This 
recently expanded field in immunology is gaining even more atten-
tion since causal connections are emerging between alterations of 
resident	macrophage	immunometabolism	and	pathologic	conditions,	
such as atherosclerosis and neurodegenerative diseases.30-32
Importantly,	 the	 possibility	 to	 activate	 NRF2	 by	 pharmaco-
logic agents during inflammatory conditions may have interesting 
consequences	 for	 pathologies	 characterized	 by	 unrestrained	 in-
flammatory	responses.	In	fact,	genetic	polymorphisms	of	the	Nrf2 
gene	 promoter	 region,	 that	 result	 in	 reduced	 expression	 of	 this	
transcription	 factor,	are	associated	with	an	 increased	susceptibil-
ity to inflammatory diseases in mouse models and humans.33,34 
Moreover,	endogenous	proteins,	such	as	GSK3	and	PTEN,	reduce	
NRF2	activation	 and	may	be	 involved	 in	providing	unopposed	or	
more	efficient	inflammatory	effects	through	the	inability	of	NRF2	
to counteract macrophage pro-inflammatory activation.11,35 On 
the	other	hand,	activation	of	NRF2	has	been	associated	with	sev-
eral	 diseases,	 including	 cancer.16,36 Considering the detrimental 
role played by anti-inflammatory macrophages in cancer develop-
ment,	NRF2-mediated	 interference	with	 classic	pro-inflammatory	
signaling might influence macrophage immunometabolic conver-
sion and favor the development of a tolerant phenotype that con-
curs in cancer development.
In	 summary,	 our	 study	 demonstrates	 that	 NRF2	 activation	 by	
chemical agents modifies immune and metabolic gene expression re-
ducing inflammatory and proliferative responses in peritoneal mac-
rophages.	These	effects	were	related	to	the	interference	with	NFκB 
and consequent effects on gene expression. This study strongly sup-
ports	 the	hypothesis	 that	 the	pharmacological	 regulation	of	NRF2	
changes	macrophage	phenotypic	activation,	suggesting	that	NRF2	is	
a useful target for inflammatory-related diseases.
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